Grzegorz Czyzewicz

Krakow, MA, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial.

Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial.

Journal: Lancet (London, England)

Published: April 01, 2025

Pembrolizumab-combination therapy for NSCLC- effectiveness and predictive factors in real-world practice.

Pembrolizumab-combination therapy for NSCLC- effectiveness and predictive factors in real-world practice.

Journal: Frontiers in oncology

Published: November 19, 2023

Treatment Patterns, Testing Practices, and Outcomes in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer in Poland: A Descriptive Analysis of National, Multicenter, Real-World Data from the REFLECT Study.

Treatment Patterns, Testing Practices, and Outcomes in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer in Poland: A Descriptive Analysis of National, Multicenter, Real-World Data from the REFLECT Study.

Journal: Cancers

Published: January 24, 2023

Detection of EGFR mutations in liquid biopsy samples using allele-specific quantitative PCR: A comparative real-world evaluation of two popular diagnostic systems.

Detection of EGFR mutations in liquid biopsy samples using allele-specific quantitative PCR: A comparative real-world evaluation of two popular diagnostic systems.

Journal: Advances in medical sciences

Published: May 11, 2021

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 15, 2021

Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03).

Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03).

Journal: Therapeutic advances in medical oncology

Published: September 01, 2020

Effectiveness of osimertinib in patients with lung adenocarcinoma in clinical practice - the Expanded Drug Access Program in Poland.

Effectiveness of osimertinib in patients with lung adenocarcinoma in clinical practice - the Expanded Drug Access Program in Poland.

Journal: Advances in respiratory medicine

Published: November 14, 2019

Altered fibrin clot properties in advanced lung cancer: impact of chemotherapy.

Altered fibrin clot properties in advanced lung cancer: impact of chemotherapy.

Journal: Journal of thoracic disease

Published: February 13, 2019

Altered fibrin clot properties in advanced lung cancer: strong impact of cigarette smoking.

Altered fibrin clot properties in advanced lung cancer: strong impact of cigarette smoking.

Journal: Medical oncology (Northwood, London, England)

Published: December 20, 2018

Decreased Levels of Histidine-Rich Glycoprotein in Advanced Lung Cancer: Association with Prothrombotic Alterations.

Decreased Levels of Histidine-Rich Glycoprotein in Advanced Lung Cancer: Association with Prothrombotic Alterations.

Journal: Disease markers

Published: November 16, 2018

The expression of circulating miR-504 in plasma is associated with EGFR mutation status in non-small-cell lung carcinoma patients.

The expression of circulating miR-504 in plasma is associated with EGFR mutation status in non-small-cell lung carcinoma patients.

Journal: Cellular and molecular life sciences : CMLS

Published: October 04, 2018

The comparison between Caprini and Padua VTE risk assessment models for hospitalised cancer patients undergoing chemotherapy at the tertiary oncology department in Poland: is pharmacological thromboprophylaxis overused?

The comparison between Caprini and Padua VTE risk assessment models for hospitalised cancer patients undergoing chemotherapy at the tertiary oncology department in Poland: is pharmacological thromboprophylaxis overused?

Journal: Contemporary oncology (Poznan, Poland)

Published: December 15, 2017

Showing 1-12 of 14

Last Updated: 09/26/2026